Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Tilray Brands Inc TLRY

Alternate Symbol(s):  T.TLRY

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol... see more

NDAQ:TLRY - Post Discussion

Tilray Brands Inc > Tilray Brands - Germany
View:
Post by Ventura2020 on Feb 26, 2024 9:47am

Tilray Brands - Germany

Medical Act Passed in Germany

Tilray Medical's Chief Strategy Officer and Head of International Denise Faltischek comments: "The decision to open up the previously limited German medical cannabis market is an important step that will allow patients and physicians to explore effective treatment options tailored to individual needs."

https://nutraceuticalbusinessreview.com/medical-cannabis-act-Germany

"Facilitating access to the highest quality cannabis medicines through the new Medical Cannabis Act, produced in Germany, will help to improve patient care and provide patients with a wider range of treatment options."

Tilray Medical looks forward to working with numerous partners to utilise the production capacity at Tilray’s state of the art Neumnster site, which is one of only three cannabis cultivation facilities located in Germany, in order to ensure that patients have improved access to the highest quality cannabis medicines.

As a leader in the field of medical cannabis research and production, Tilray Medical strongly believes that these developments will have a positive impact on the health and well-being of many patients in Germany.

 
Comment by slottygoddy on Feb 26, 2024 9:54am
Means, TILRAY's market share will at the very best be half of what it is today. 
Comment by Vulcan on Feb 26, 2024 9:57am
Tlry market share in germany is 20 percent.. medical..  its exspected to be approx 400 mil this yr or 80 mil for tlry.. but who knows for sure.. it may be more
Comment by slottygoddy on Feb 26, 2024 10:07am
IMO, with new entries etc, i suspect it'll drop to 10%.  At best $25 to $40mm. Keep in mind, Germany's economy is very weak right now.
Comment by DaveInCalgary on Feb 26, 2024 1:45pm
Germany: Fact and Fiction Cannabis Sector Equity Research   26 February 2024 Pablo Zuanic ZUANIC & ASSOCIATES pablo.zuanic@zuanicgroup.com 420Odysseus; www.zuanicassociates.com https://zuanic.worldflowconnect.net/open/0176c2c4-ad2a-43a8-ae32-d90a3df0d0cf/240226%20Germany.pdf/07a73660-9328-46e2-9df8-6a8c563abaf9 Few remarks: "While Friday was good for global cannabis, we are ...more  
Comment by DaveInCalgary on Feb 26, 2024 2:25pm
”Tilray supplies Germany from Portugal for the most part. Curaleaf acquired an EU GMP facility in Portugal from Clever Leaves”   “Among US MSOs, a Curaleaf affiliate, Curaleaf International Holdings Limited (68.5% owned by CURLF; the owners of the other 31.5% have not been disclosed) owns a German importer (Four20 Pharma), sourcing from Canadian producers”   For Jan-Sep 2023 ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities